Chembridge Corporation
Records under this name other than patents Chembridge Corporation holds now: patents now held by others, patents whose terms have ended, and its applications, pending or abandoned.
Showing 1 to 10 of 10 · Back to Chembridge Corporation
Confidence:Highevery input resolvedMediumone input unresolvedLowtwo or more caveatsUSPTO recordfrom USPTO's bulk records, without the patent's file history
| Patent | Title | Status | Expires | Confidence |
|---|---|---|---|---|
| US 9,273,055 | Tyrosine kinase inhibitors Lapsed on the fee record Ended Mar 1, 2024 · USPTO record | Lapsed on the fee record | Ended Mar 1, 2024 | USPTO record |
| US 9,249,147 | Tyrosine kinase inhibitors Lapsed on the fee record Ended Feb 2, 2024 · USPTO record | Lapsed on the fee record | Ended Feb 2, 2024 | USPTO record |
| US 8,063,225 | Tricyclic compound derivatives useful in the treatment of neoplastic diseases, inflammatory disorders and immunomodulatory disorders Lapsed on the fee record Ended Nov 22, 2023 · USPTO record | Lapsed on the fee record | Ended Nov 22, 2023 | USPTO record |
| US 8,629,147 | Heterocyclic compounds useful in the treatment of neoplastic diseases, inflammatory disorders and immunomodulatory disorders Lapsed on the fee record Ended Jan 14, 2022 · USPTO record | Lapsed on the fee record | Ended Jan 14, 2022 | USPTO record |
| US 9,290,503 | Tricyclic compound derivatives useful in the treatment of neoplastic diseases, inflammatory disorders and immunomodulatory disorders Lapsed on the fee record Ended Mar 22, 2020 · USPTO record | Lapsed on the fee record | Ended Mar 22, 2020 | USPTO record |
| US 7,915,260 | Urotensin II receptor antagonists Formerly held Lapsed on the fee record Ended Mar 29, 2019 · USPTO record | Lapsed on the fee record | Ended Mar 29, 2019 | USPTO record |
| US 8,822,500 | Tyrosine kinase inhibitors Lapsed on the fee record Ended Sep 2, 2018 · USPTO record | Lapsed on the fee record | Ended Sep 2, 2018 | USPTO record |
| US 8,815,906 | Tyrosine kinase inhibitors Lapsed on the fee record Ended Aug 26, 2018 · USPTO record | Lapsed on the fee record | Ended Aug 26, 2018 | USPTO record |
| US 8,686,005 | Tricyclic compound derivatives useful in the treatment of neoplastic diseases, inflammatory disorders and immunomodulatory disorders Lapsed on the fee record Ended Apr 1, 2018 · USPTO record | Lapsed on the fee record | Ended Apr 1, 2018 | USPTO record |
| US 6,872,827 | Somatostatin analogue compounds Lapsed on the fee record Ended Mar 29, 2013 · USPTO record | Lapsed on the fee record | Ended Mar 29, 2013 | USPTO record |